PLK1 and neoplasm: The present results indicate that the clinically relevant PLK1 inhibitor volasertib interacts synergistically with the approved HDACI belinostat reduce tumor growth in diverse NHL cell types both in vitro and in vivo, and suggest that the mechanisms underlying this phenomenon are likely to be multifactorial.